Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Acquisitions & Divestments (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Acquisitions & Divestments fell 99.97% year-over-year to $1000.0, compared with a TTM value of $20.7 million through Sep 2025, down 41.05%, and an annual FY2024 reading of $28.5 million, down 86.33% over the prior year.
  • Change in Acquisitions & Divestments was $1000.0 for Q3 2025 at Atara Biotherapeutics, down from $17.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $89.2 million in Q1 2022 and bottomed at $1000.0 in Q3 2025.
  • Average Change in Acquisitions & Divestments over 4 years is $39.1 million, with a median of $33.9 million recorded in 2022.
  • Peak annual rise in Change in Acquisitions & Divestments hit 15.86% in 2025, while the deepest fall reached 99.97% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $50.7 million in 2022, then tumbled by 80.29% to $10.0 million in 2023, then tumbled by 65.3% to $3.5 million in 2024, then tumbled by 99.97% to $1000.0 in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ATRA at $1000.0 in Q3 2025, $17.2 million in Q1 2025, and $3.5 million in Q4 2024.